Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of EKB-569 in Subjects With Advanced Non-Small Cell Lung Cancer

NCT00067548 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00067548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00067548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of EKB-569 in Subjects With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
January 31, 2005
Enrollment
44 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, lung neoplasms, non-small-cell lung carcinoma